These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 34919963)
1. The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation. Zeng Q; Lu W; Deng Z; Zhang B; Wu J; Chai J; Chen X; Xu X J Biol Chem; 2022 Jan; 298(1):101497. PubMed ID: 34919963 [TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory effects of FS48, the first potassium channel inhibitor from the salivary glands of the flea Xenopsylla cheopis. Deng Z; Zeng Q; Tang J; Zhang B; Chai J; Andersen JF; Chen X; Xu X J Biol Chem; 2021; 296():100670. PubMed ID: 33864815 [TBL] [Abstract][Full Text] [Related]
3. Acacetin blocks kv1.3 channels and inhibits human T cell activation. Zhao N; Dong Q; Fu XX; Du LL; Cheng X; Du YM; Liao YH Cell Physiol Biochem; 2014; 34(4):1359-72. PubMed ID: 25301362 [TBL] [Abstract][Full Text] [Related]
4. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases. Ye F; Hu Y; Yu W; Xie Z; Hu J; Cao Z; Li W; Wu Y Toxins (Basel); 2016 Apr; 8(4):115. PubMed ID: 27104568 [TBL] [Abstract][Full Text] [Related]
5. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670 [TBL] [Abstract][Full Text] [Related]
6. The Xiong W; Fan H; Zeng Q; Deng Z; Li G; Lu W; Zhang B; Lai S; Chen X; Xu X Acta Pharm; 2023 Mar; 73(1):145-155. PubMed ID: 36692462 [TBL] [Abstract][Full Text] [Related]
7. Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties. Zhao N; Dong Q; Qian C; Li S; Wu QF; Ding D; Li J; Wang BB; Guo KF; Xie JJ; Cheng X; Liao YH; Du YM Sci Rep; 2015 Nov; 5():17381. PubMed ID: 26616555 [TBL] [Abstract][Full Text] [Related]
8. 18β-Glycyrrhetinic acid potently inhibits Kv1.3 potassium channels and T cell activation in human Jurkat T cells. Fu XX; Du LL; Zhao N; Dong Q; Liao YH; Du YM J Ethnopharmacol; 2013 Jul; 148(2):647-54. PubMed ID: 23707333 [TBL] [Abstract][Full Text] [Related]
10. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases. Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605 [TBL] [Abstract][Full Text] [Related]
11. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253 [TBL] [Abstract][Full Text] [Related]
12. Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway. Fellerhoff-Losch B; Korol SV; Ganor Y; Gu S; Cooper I; Eilam R; Besser M; Goldfinger M; Chowers Y; Wank R; Birnir B; Levite M J Neural Transm (Vienna); 2016 Mar; 123(3):137-57. PubMed ID: 26611796 [TBL] [Abstract][Full Text] [Related]
13. Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells. Zhao N; Dong Q; Du LL; Fu XX; Du YM; Liao YH PLoS One; 2013; 8(5):e64629. PubMed ID: 23717641 [TBL] [Abstract][Full Text] [Related]
15. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290 [TBL] [Abstract][Full Text] [Related]
16. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388 [TBL] [Abstract][Full Text] [Related]
17. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054 [TBL] [Abstract][Full Text] [Related]
18. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841 [TBL] [Abstract][Full Text] [Related]
19. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724 [TBL] [Abstract][Full Text] [Related]
20. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]